6,155 Shares in Stryker Corporation $SYK Acquired by AlpenGlobal Capital LLC

Key Points

• AlpenGlobal Capital LLC acquired 6,155 Stryker shares worth approximately $1.94 million in the second quarter, while institutional investors collectively own 77.09% of the company.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $386.28. Stryker recently exceeded quarterly EPS expectations and reported 9.4% year-over-year revenue growth.
• Stryker shares opened at $327.97, down 3.5%, amid substantial insider selling totaling 665,370 shares worth about $216.2 million over the past 90 days. The company also declared a quarterly dividend of $0.88 per share, yielding approximately 1.1% annually.

AlpenGlobal Capital LLC bought a new stake in Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,155 shares of the medical technology company's stock, valued at approximately $1,938,000. Stryker makes up about 1.2% of AlpenGlobal Capital LLC's investment portfolio, making the stock its 26th biggest position.

Several other hedge funds have also bought and sold shares of SYK. Norges Bank bought a new position in shares of Stryker in the 4th quarter worth $1,822,272,000. Auto Owners Insurance Co lifted its holdings in shares of Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock worth $1,024,444,000 after acquiring an additional 2,906,448 shares during the last quarter. Flossbach Von Storch SE purchased a new position in Stryker in the second quarter worth $464,506,000. Wellington Management Group LLP grew its position in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company's stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares in the last quarter. Finally, Corient Private Wealth LLC increased its stake in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company's stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Raymond James Financial set a $370.00 price target on Stryker in a research note on Friday, July 31st. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research report on Friday, May 1st. BMO Capital Markets began coverage on Stryker in a report on Wednesday, July 8th. They set an "outperform" rating and a $369.00 price objective on the stock. Citizens Jmp dropped their target price on Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research report on Monday, August 3rd. Finally, Robert W. Baird set a $385.00 target price on Stryker in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of "Moderate Buy" and a consensus price target of $386.28.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company's stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 665,370 shares of company stock valued at $216,238,501. Corporate insiders own 4.60% of the company's stock.

Stryker Stock Down 3.5%

Shares of NYSE:SYK opened at $327.97 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a market cap of $125.80 billion, a PE ratio of 33.99, a P/E/G ratio of 2.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock's 50-day moving average is $326.64 and its 200 day moving average is $332.66.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm's revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker's payout ratio is presently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source